Medigene Investor Relations Material
Latest events
Status Update
Medigene
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Medigene AG
Access all reports
Medigene AG is a biotechnology company specializing in the development of T cell-based immunotherapies for cancer treatment. The company focuses on engineered T cell receptors (TCRs) and dendritic cell vaccines to enhance the body's immune response against tumors. Its research and development efforts aim to create innovative therapies that improve targeted cancer treatment options. The company is headquartered in Planegg, Germany, and its shares are listed on the Frankfurt Stock Exchange (FSE).
Key slides for Medigene AG
R&D Event
Medigene AG
H1 2024
Medigene AG
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
MDG1
Country
🇩🇪 Germany